Novo Nordisk launches new diabetic device
Добавлено: 13.09.2008, 20:55
The $7.8 billion Danish insulin giant Novo Nordisk has announced the launch of a new FlexPen, an insulin injection device. With the launch of its new product, the company expects its position will be further strengthened in the global insulin market that has been witnessing brutal competition among insulin makers in recent years.
Currently, the Danish pharmaceutical group controls 53% of the total insulin market and 43% of the modern insulin market, by volume.
“This new generation of FlexPen is very welcome because it makes the injection process more comfortable for patients,” said professor Andreas Pfutzner from the Institute for Clinical Research and Development in Germany, participating at the European Association of the Study of Diabetes (EASD) annual meeting held recently in Rome.
Pfutzner said, “It introduces key features that will go a long way towards improving their compliance with the prescribed treatment.”
The device will be available to patients around the world from late 2008 onwards.
Among the new design features are coloured cartridges, labels and packaging designed to aid insulin type identification for patients. For ease of handling everyday insulin injections, the next generation device has a simple twist mechanism to attach and detach the needles. This makes the device the first pen to be designed for use with a new generation of needles, which have a patented attachment interface.
The new FlexPen requires 30% less force when injecting, resulting in a significantly lower injection force compared to the earlier one.
Currently, there are 3 different insulin pens from Novo Nordisk available in India - the durable pen device NovoPen 3, the prefilled disposable pen device NovoLet and the newest prefilled disposable insulin pen FlexPen. In India, the FlexPen device is available for insulin aspart and premix insulin analogue.
The next generation of FlexPen has been tested among patients to assess if the new features translated into actual patient preference. In total, 95% of patients who tried the new device said they would prefer to use it.
Estimates show that the count of diabetic patients will increases to 38 crore patients by 2025 from 24.6 crore in 2007. Diabetes affects 8% of Indian as well as US population. In India, this equates to 41 million people, compared to 19 million in the US. FlexPen contains 300 units of injectable insulin for the management of Type 1 and Type 2 diabetes.
Currently, the Danish pharmaceutical group controls 53% of the total insulin market and 43% of the modern insulin market, by volume.
“This new generation of FlexPen is very welcome because it makes the injection process more comfortable for patients,” said professor Andreas Pfutzner from the Institute for Clinical Research and Development in Germany, participating at the European Association of the Study of Diabetes (EASD) annual meeting held recently in Rome.
Pfutzner said, “It introduces key features that will go a long way towards improving their compliance with the prescribed treatment.”
The device will be available to patients around the world from late 2008 onwards.
Among the new design features are coloured cartridges, labels and packaging designed to aid insulin type identification for patients. For ease of handling everyday insulin injections, the next generation device has a simple twist mechanism to attach and detach the needles. This makes the device the first pen to be designed for use with a new generation of needles, which have a patented attachment interface.
The new FlexPen requires 30% less force when injecting, resulting in a significantly lower injection force compared to the earlier one.
Currently, there are 3 different insulin pens from Novo Nordisk available in India - the durable pen device NovoPen 3, the prefilled disposable pen device NovoLet and the newest prefilled disposable insulin pen FlexPen. In India, the FlexPen device is available for insulin aspart and premix insulin analogue.
The next generation of FlexPen has been tested among patients to assess if the new features translated into actual patient preference. In total, 95% of patients who tried the new device said they would prefer to use it.
Estimates show that the count of diabetic patients will increases to 38 crore patients by 2025 from 24.6 crore in 2007. Diabetes affects 8% of Indian as well as US population. In India, this equates to 41 million people, compared to 19 million in the US. FlexPen contains 300 units of injectable insulin for the management of Type 1 and Type 2 diabetes.